Pharmacokinetics of rocuronium bromide in obese female patients

European Journal of Anaesthesiology

Volumn 16, Issue 8, 1999, Pages 507-510

  Puhringer F K ^a   Keller, C ^a   Kleinsasser, A ^a   Giesinger, S ^a   Benzer, A ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Complications: obesity; Neuromuscular relaxants: rocuronium; Pharmacokinetics: obesity; Potency: obesity

Indexed keywords

NEUROMUSCULAR BLOCKING AGENT; ROCURONIUM;

ADULT; ANESTHESIA; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GYNECOLOGIC SURGERY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MEAN RESIDENCE TIME; OBESITY; PLASMA CLEARANCE; TIME;

ADULT; ANDROSTANOLS; ANESTHESIA; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HALF-LIFE; HUMANS; NEUROMUSCULAR NONDEPOLARIZING AGENTS; OBESITY; SKIN TEMPERATURE; SYNAPTIC TRANSMISSION;

EID: 0344199408     PISSN: 02650215     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2346.1999.00523.x     Document Type: Article

References (11)

1. Weinstein JA, Matteo RS, Ornstein E et al. Pharmacodynamics of vecuronium and atracurium in the obese patient. Anesth Analg 1988; 67: 1149-1153.
2. Schwartz AE, Matteo RS, Ornstein E et al. Pharmacokinetics and pharmacodynamics in the obese surgical patient. Anesth Analg 1992; 74: 515-518.
3. Pühringer FK, Khuenl-Brady KS, Mitterschiffthaler G. Rocuronium bromide: time course of action in underweight, normal weight, overweight and obese patients. Eur J Anaesthesiol 1995; 12 (Suppl. 11): 107-110.
4. Kleef UW, Proost JH, Roggeveld J et al. Determination of rocuronium and its putative metabolites in body fluids and tissue homogenates. J Chromatogr 1993; 621: 65-67.
5. Wagner JG. Fundamentals of Clinical Pharmacokinetics. Hamilton, Illinois: Drug Intelligence Publications, 1975.
6. Wierda JMKH, Kleef UW, Lambalk LM et al. The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth 1991; 38: 430-435.
7. Cooper RA, Maddenini VR, Mirakhur RK et al. Time course of action and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. Br J Anaesth 1993; 71: 222-226.
8. Fisher DM, Rosen JI. A pharmacokinetic explanation for increased recovery time following larger or repeated doses of non-depolarizing muscle relaxants. Anesthesiology 1986; 65: 286-291.
9. McCoy EP, Mirhakur RK, Maddenini VR et al. Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. Br J Anaesth 1996; 76: 29-33.
10. Szenohradszky J, Fisher DM, Segredo V et al. Pharmacokinetics of rocuronium bromide (Org 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. Anesthesiology 1992; 77: 899-904.
11. Shanks CA, Frangen RJ, Ling D. Continuous intravenious infusion of rocuronium (Org 9426) in patients receiving balanced, enflurane, or isoflurane anaesthesia. Anesthesiology 1993; 78: 649-651.